If you can't read please download the document

Zejula, INN - niraparib...al 2006; Jelovac D et al. 2011). The World Health Organization (WHO) classification of surface epithelial ovarian tumours includes six major histotypes -

Download PDF Report

Upload
others
View
1
Download
0

Embed Size (px)

AUSTRALIAN PRODUCT INFORMATION ZEJULA (NIRAPARIB)

AUSTRALIAN PRODUCT INFORMATION ZEJULA (NIRAPARIB)

Documents

Begoña Garcia Mariñoso, Izabela Jelovac, Pau Olivella To

Begoña Garcia Mariñoso, Izabela Jelovac, Pau Olivella To

Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION …...≥1,500/µL or hemoglobin returns to ≥9 g/dL. •Resume ZEJULA at a reduced dose per Table 1. •Discontinue ZEJULA if neutrophils and/or

HIGHLIGHTS OF PRESCRIBING INFORMATION …...≥1,500/µL or hemoglobin returns to ≥9 g/dL. •Resume ZEJULA at a reduced dose per Table 1. •Discontinue ZEJULA if neutrophils and/or

Documents

Pr ZEJULA - pdf.hres.ca

Pr ZEJULA - pdf.hres.ca

Documents

Prior Authorization Criteria · 2020-06-20 · Prior Authorization with Quantity Limit Program Summary. ... Sun Pharmaceuticals Inc. June 2018. 82. Zejula prescribing information

Prior Authorization Criteria · 2020-06-20 · Prior Authorization with Quantity Limit Program Summary. ... Sun Pharmaceuticals Inc. June 2018. 82. Zejula prescribing information

Documents

Begoña Garcia Mariñoso, Izabela Jelovac, Pau Olivella · Madrid, Université de Liège and University College Dublin. On the real world cases, we have greatly benefited from discussions

Begoña Garcia Mariñoso, Izabela Jelovac, Pau Olivella · Madrid, Université de Liège and University College Dublin. On the real world cases, we have greatly benefited from discussions

Documents

Zejula® (niraparib) Prescribing Information 5.4 Embryo-Fetal Toxicity Based on its mechanism of action, ZEJULA can cause fetal harm when administered to a pregnant woman [see Clinical

Zejula® (niraparib) Prescribing Information 5.4 Embryo-Fetal Toxicity Based on its mechanism of action, ZEJULA can cause fetal harm when administered to a pregnant woman [see Clinical

Documents

Zejula® (niraparib) Prescribing Information · administration may be a potential method for managing nausea. Patients should start treatment with ZEJULA no later than 8 weeks after

Zejula® (niraparib) Prescribing Information · administration may be a potential method for managing nausea. Patients should start treatment with ZEJULA no later than 8 weeks after

Documents

The Scandinavian Sarcoma Group annual report on extremity ...The data from Sweden does not include head and neck BS. Totals per center 2012-2016 Histotypes Bone sarcomas (BS) are classified

The Scandinavian Sarcoma Group annual report on extremity ...The data from Sweden does not include head and neck BS. Totals per center 2012-2016 Histotypes Bone sarcomas (BS) are classified

Documents

Izabela Jelovac, Samuel Nzale To cite this version...Izabela Jelovac, Samuel Kembou Nzale Abstract: We study optimal contracts in a regulator-agent setting with joint production, altruistic

Izabela Jelovac, Samuel Nzale To cite this version...Izabela Jelovac, Samuel Kembou Nzale Abstract: We study optimal contracts in a regulator-agent setting with joint production, altruistic

Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION These …...• Resume ZEJULA at same or reduced dose per Table 1. • If platelet count is

HIGHLIGHTS OF PRESCRIBING INFORMATION These …...• Resume ZEJULA at same or reduced dose per Table 1. • If platelet count is

Documents

ODSJEK ZA FONETIKU FILOZOFSKOG FAKULTETA ...Narativna analiza u osoba s afazijom 11.45 ‐ 12.00 Nina Č olovi ć, Dorotea Rosandi ć, Zdravka Bio č ina, Eva Feldman, Tara Jelovac,

ODSJEK ZA FONETIKU FILOZOFSKOG FAKULTETA ...Narativna analiza u osoba s afazijom 11.45 ‐ 12.00 Nina Č olovi ć, Dorotea Rosandi ć, Zdravka Bio č ina, Eva Feldman, Tara Jelovac,

Documents

A Phase 2, Single-Arm, Open-label Study to Evaluate the ... · chemotherapy.2,3 • Niraparib (ZEJULA®) is a selective, orally active PARP-1 and -2 inhibitor approved for the maintenance

A Phase 2, Single-Arm, Open-label Study to Evaluate the ... · chemotherapy.2,3 • Niraparib (ZEJULA®) is a selective, orally active PARP-1 and -2 inhibitor approved for the maintenance

Documents

De-identification of French medical narratives...Circulation. 2000 Jun 13;101(23):E215-20. [12] JaćimovićJ, Krstev C, Jelovac D. A Rule-Based System for Automatic De-identification

De-identification of French medical narratives...Circulation. 2000 Jun 13;101(23):E215-20. [12] JaćimovićJ, Krstev C, Jelovac D. A Rule-Based System for Automatic De-identification

Documents

47976 tesnbb MU - ZEJULA...Resume ZEJULA at same or reduced dose per Table 1 If platelet count is

47976 tesnbb MU - ZEJULA...Resume ZEJULA at same or reduced dose per Table 1 If platelet count is

Documents

Popcorn Pricing, the Hippocratic Oath, and Health Care ... Jelovac... · Movie Theatre Popcorn Five key features: Don’t let you carry in your own food ⇒ Monopoly. Prices are high

Popcorn Pricing, the Hippocratic Oath, and Health Care ... Jelovac... · Movie Theatre Popcorn Five key features: Don’t let you carry in your own food ⇒ Monopoly. Prices are high

Documents

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS...Treatment with Zejula should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. Posology

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS...Treatment with Zejula should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. Posology

Documents

ZEJULA Product Monograph - GSK · Page 4of 30 PARTI: HEALTH PROFESSIONALINFORMATION 1 INDICATIONS ZEJULATM(niraparib capsules) is indicated as monotherapy for the maintenance treatment

ZEJULA Product Monograph - GSK · Page 4of 30 PARTI: HEALTH PROFESSIONALINFORMATION 1 INDICATIONS ZEJULATM(niraparib capsules) is indicated as monotherapy for the maintenance treatment

Documents

Miscellaneous Oncology Drugsprogression more than 6 months after completion of the last round of platinum therapy Zejula® (niraparib) may be considered medically necessary for the

Miscellaneous Oncology Drugsprogression more than 6 months after completion of the last round of platinum therapy Zejula® (niraparib) may be considered medically necessary for the

Documents

Pathway Landscapes and Epigenetic Regulation in Breast ... · Epigenetic variation is a main regulation mechanism of gene expression in various cancer histotypes, and due to its reversibility,

Pathway Landscapes and Epigenetic Regulation in Breast ... · Epigenetic variation is a main regulation mechanism of gene expression in various cancer histotypes, and due to its reversibility,

Documents

Cytology and DNA Analysis of Ameloblastoma - A Case Report. · Virag3, Dalibor Frančeski4, Zorana Lipšanski1 and Spomenka ... Golubović M, Petrović M, Jelovac DB, Nenezić DU,

Cytology and DNA Analysis of Ameloblastoma - A Case Report. · Virag3, Dalibor Frančeski4, Zorana Lipšanski1 and Spomenka ... Golubović M, Petrović M, Jelovac DB, Nenezić DU,

Documents

ZEJULA (niraparib) Together With GSK Oncology Enrollment Form€¦ · Together with GSK Oncology Enrollment Form. Fax completed enrollment form to 1-800-645-9043 For assistance, please

ZEJULA (niraparib) Together With GSK Oncology Enrollment Form€¦ · Together with GSK Oncology Enrollment Form. Fax completed enrollment form to 1-800-645-9043 For assistance, please

Documents

Zejula (niraparib) capsules - GSKpro

Zejula (niraparib) capsules - GSKpro

Documents

Business and Government Ethics in the ‘New’ and Old’ EU...1 Cite as: Jelovac, D., Van der Wal, Z. & A. Jelovac (2011). Business and Government Ethics in the ‘New’ and ‘Old’

Business and Government Ethics in the ‘New’ and Old’ EU...1 Cite as: Jelovac, D., Van der Wal, Z. & A. Jelovac (2011). Business and Government Ethics in the ‘New’ and ‘Old’

Documents

Towards sustainable waterfront transformation: through … · Towards sustainable waterfront transformation: through the Mediterranean to Montenegro S. R. Jelovac Department for Environmental

Towards sustainable waterfront transformation: through … · Towards sustainable waterfront transformation: through the Mediterranean to Montenegro S. R. Jelovac Department for Environmental

Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION Continue …€¦ · Resume ZEJULA at same or reduced dose per Table 1. If platelet count is

HIGHLIGHTS OF PRESCRIBING INFORMATION Continue …€¦ · Resume ZEJULA at same or reduced dose per Table 1. If platelet count is

Documents

RESEARCH ARTICLE Open Access Molecular fingerprinting ......RESEARCH ARTICLE Open Access Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas

RESEARCH ARTICLE Open Access Molecular fingerprinting ......RESEARCH ARTICLE Open Access Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas

Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights …€¦ · • Resume ZEJULA at same or reduced dose per Table 1. • If platelet count is

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights …€¦ · • Resume ZEJULA at same or reduced dose per Table 1. • If platelet count is

Documents

CANCER THERAPY Copyright © 2018 Modeling chemotherapy ... · (Zejula, Tesaro Inc.)—in BRCA mutant high-grade ovarian cancer prove that the DNA damage repair pathway can successfully

CANCER THERAPY Copyright © 2018 Modeling chemotherapy ... · (Zejula, Tesaro Inc.)—in BRCA mutant high-grade ovarian cancer prove that the DNA damage repair pathway can successfully

Documents